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56 Poster Session Irecommendation. This includes patients who received only one of
a recommended tandem autologous HSCT, or who received an au-
tologous rather than a recommended allogeneic procedure. But
given the limitations of this analysis, we conclude that restrictions
imposed by health insurance coverage lead to significant delays in
implementing the treatment plan for patients who receive HSCT.147
MEASURING THE SYMPTOM BURDENOF CHRONIC GRAFT VERSUS HOST
DISEASE
Williams, L.A.1, Neumann, J.L.2, Couriel, D.R.3, Mendoza, T.R.1,
White, M.H.1, Zhang, Y.1, Cleeland, C.S.1 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2The University of Texas
MD Anderson Cancer Center, Houston, TX; 3Sarah Cannon Cancer
Center and Tennessee Oncology, Nashville, TN.
Significance: Chronic graft-versus-host disease (cGVHD) is an
autoimmune-like reaction that causes debilitating symptoms fol-
lowing allogeneic hematopoietic stem cell transplantation (al-
loHSCT). The major barrier to good management of these
symptoms is inadequate assessment. Theoretical Framework:
Symptom burden is the combined impact of all symptoms on a per-
son’s ability to function as one did prior to onset of disease and ther-
apy.Problem andPurpose:There is scant literature addressing the
symptom burden of cGVHD. Symptoms are subjective phenomena
and can only be accurately measured by patient report. The pur-
poses of this research are to develop a short, easily understood, valid,
and reliable patient questionnaire for measuring cGVHD symptom
burden and to describe the symptom burden of cGHVD. This ab-
stract reports preliminary results.Methods: The 13 core symptom
items and 6 interference items of the M. D. Anderson Symptom In-
ventory (MDASI), rated on a scale of 0 to 10, are the base for the
MDASI-GVH. In addition, 14 cGVHD-specific symptom items
were generated from interviews with patients and the ratings of an
expert panel. 128 patients with cGVHD and 64 patients post al-
loHSCTwithout cGVHDwill complete the MDASI-GVH. Infor-
mation on performance status, quality of life, and a repeat MDASI
will be collected on patients with cGVHD. Psychometric analyses
will reduce the number of items to the optimal set describing symp-
tom burden, determine predictive and discriminant validity, and es-
tablish internal consistency and test-retest reliability. The symptom
burden of cGVHD will be described through descriptive, correla-
tional, cluster, and factor analyses. Results: To date, 31 patients
with cGVHD and 7 without have completed the MDASI-GVH.
Average age is 49.3 years and 50% are male. Symptom severity
and interference is displayed in Table 1. Patients with cGVHD re-
ported a unique cluster of severe symptoms that included skin prob-
lems, eye problems, muscle weakness, and joint stiffness. By
February of 2008, we will report data on 45 patients with cGVHD
and 20 patients without cGVHD. Implications: Patients with
cGVHD tend to report more symptom severity and interference
than patients post alloHSCT without cGVHD. The most severe
symptoms patients with cGVHD report are cGVHD-specific. Fur-
ther testing is ongoing, but the MDASI-GVH is an easily com-
pleted method of quantifying symptoms of cGVHD for clinician
monitoring and use in trials testing methods to treat cGVHD.
Table 1. Symptom Severity and Interference in Patients With and
Without cGVHD
cGVHD No cGVHDItem Mean SD Mean SDSeverity of 13
Core Symptoms1.91 1.41 1.45 1.40Severity of 14 cGVHD-
Specific Symptoms2.24 1.41 1.53 0.87Severity of All Symptom 2.05 1.33 1.49 1.05
Symptom Interference 2.80 2.19 2.60 1.75SD 5 standard deviation.148
LONG-TERM NEUROCOGNITIVE FUNCTION OF PEDIATRIC PATIENTS
WITH SEVERE COMBINED IMMUNE DEFICIENCY (SCID): PRE AND
POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Lin, M.1, Epport, K.2, Azen, C.2, Shah, A.J.3 1Keck School of Medicine,
Los Angeles, CA; 2Childrens Hospital Los Angeles, Los Angeles, CA;
3Childrens Hospital Los Angeles, Los Angeles, CA.
Background: Hematopoietic stem cell transplantation (HSCT)
is the only cure for patients with severe combined immunodefi-
ciency (SCID). The purpose of this study is to evaluate long-term
neurocognitive function of patients with SCID following myeloa-
blative chemotherapy and HSCT. Materials and Methods: Six-
teen pediatric patients diagnosed with SCID were tested using the
Bayley Scales of Infant Development and the validated Vineland
Adaptive Behavior Scales (VABS) pre- and 1-year post-HSCT.
Three years post HSCT there were 11 patients available for testing
and four patients were available 5 years post-HSCT. Patients
greater than 3 years of age were administered the Wechsler Pre-
school and Primary Scale of Intelligence (WPPSI). Both raw scores
and scaled scores were analyzed. Data were analyzed using multiple
regression analysis.Results:Therewas a significant decrease 1-year
post-HSCT in the Bayley Mental Developmental Index (MDI)
[92.5 (pre) vs. 70.8 (1 yr post); p5\0.0001] and the VABS [99.73
(pre) vs. 79.87 (1 year post), p5\0.0001]. There was no change
in the Bayley Psychomotor Development Scale (PDI) [82.4 (pre)
vs. 84.8 (1 year post), p 5 0.68]. There was a significant decrease
over time in the MDI [95.00 (pre) vs. 70.4 (1-year post) vs. 69.20
(3 yr post); p\ 0.0001), but no significant change between 1- and
3-years post- HSCT]. The PDI scores decreased over time [86.29
(pre) vs. 86 (1-year post) vs. 74.14 (3-years post), p 5 0.045]. Al-
though there was a decrease in scaled scores, there was not a loss
of skills. Analysis of raw scores showed that there was an increase
in the raw test scores, which indicated that these children acquired
developmental skills, but at a slower rate than normal infants and
toddlers. Conclusions: These findings may reflect the effects of
the isolation and prolonged hospitalization that characterizes the
immediate post transplant period. Patients miss out on social inter-
actions and learning opportunities that normally occur at their re-
spective stages of development. These restrictions keep patients
from acquiring developmentally appropriate cognitive skills as
well as gross and fine motor developmental milestones. Longitudi-
nal follow-up will be important to quantify acquisition of skills.LEUKEMIA149
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (Allo-HCT)
FOR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIAS: IMPACT OF IMATINIB ON RISK OF RELAPSE AND SURVIVAL
Burke, M.J.1, Trotz, B.1, Luo, X.2, DeFor, T.E.2, Burns, L.J.3,
Baker, K.S.1,Weisdorf, D.J.3,Wagner, J.E.1, Verneris, M.R.1 1Univer-
sity of Minnesota, Minneapolis, MN; 2University of Minnesota, Minne-
apolis, MN; 3University of Minnesota, Minneapolis, MN.
The utility of Imatinib use in either the pre-or-post-transplant
period for Philadelphia positive (Ph1) Acute Lymphoblastic Leu-
kemia (ALL) is unknown. Additionally, there have been concerns
regarding Imatinib and cardiac toxicity (congestive heart failure)
in some series. Therefore, we investigated the outcome of trans-
plantation in patients with Ph1 ALL and treated with Imatinib.
Thirty-two patients with Ph1 ALL received allo-HCT at the Uni-
versity of Minnesota between 1999 and 2006. The median age at
HCT was 21.9 (range; 2.8–55.2) years. Eighteen (56.3%) patients
were male. Twenty patients were in first remission (CR1) prior to
HCT and 12-patients were in second remission (CR2). Donor
source was HLA matched and mismatched unrelated umbilical
cord blood (n 5 17), HLA matched sibling bone marrow (n 5 12)
and HLA matched unrelated bone marrow (n 5 3). All patients
were conditioned with cyclophosphamide and total body irradia-
tion. GVHD prophylaxis was with CSA/MTX (n 5 15), CSA/
MMF (n 5 13) or CSA methylprednisone/ATG (n 5 4). Of the
32 patients with Ph1 ALL, fifteen received Imatinib therapy pre/
Poster Session I 57post-HCT (10-pre-HCT and 5-post-HCT) comprising the Imati-
nib group and the remaining 17-patients, who either never received
Imatinib (n 5 13) or received it at time of relapse (n 5 4), were the
non-Imatinib group. Overall survival and relapse-free survival at 2
years was 73% and 65% for the Imatinib group compared to 34%
and 35% for the non-Imatinib group (p 5 0.14 and 0.1, respec-
tively). However, the incidence of relapse for these two groups
was 8% (95%CI: 0.00, 0.24) and 41% (95%CI: 0.17, 0.66), respec-
tively (p5 0.02). Transplant related mortality at 2-years was similar
between groups (27% and 24%; p5 0.81). Of note, cardiac toxicity
[defined as a reduction in left ventricular ejection fraction of.20%
below baseline, cardiac hypertrophy or EKG abnormalities (ST
changes, T-wave abnormalities, ischemia and/or infarction)] was
less in the Imatinib group, 23% (95% CI: 0.00, 0.49) versus 47%
(95% CI: 0.22, 0.72) (p 5 0.09). In conclusion, the use of Imatinib
therapy in patients with Ph1 ALL in either the pre-or-post-HCT
setting decreases the rate of relapse with a trend toward improved
RFS and OS. Furthermore, Imatinib treated patients have no obvi-
ous increased risk of cardiac toxicity.150
GENERATION OF AUTOLOGOUS LEUKEMIA-REACTIVE CYTOLYTIC T
CELLS (CTL) USING A NOVEL EXPANSION CULTURE SYSTEM: EFFECT
OF ANTI-CTLA-4 VERSUS IL-2
Zhong, R., Lane, T.A., Ball, E.D. University of California, San Diego
School of Medicine, La Jolla, CA.
Background: Evidence supports a role for immunotherapy in
acute myelogenous leukemia (AML). We previously reported
a novel method to generate autologous AML-reactive CTL from
the blood mononuclear cells (MNC) of pts with AML. The strategy
employs differentiation of AML blasts into dendritic cells (DC) fol-
lowed by expansion of autologous CTL. We further reported that
inclusion of anti-CTLA-4 in the culture system between days 1–8
augmented the cytotoxicity and interferon-g (IFN-g) release of
the expanded T cells (Cytotherapy 2006;8(1):3012). The purpose
of the current studies was to investigate whether similar augmenta-
tion of T cell function could be achieved by low dose IL-2 during
days 1–8 of culture. Methods: Primary AML peripheral blood or
marrow MNC were cultured in 96 well plates for 7 days in AIM-
V/RPMI-1640 with 10% AB serum, GM-CSF (50 ng/ml), IL-4
(1000 u/ml), and either anti-CTLA-4 (5 mcg/ml) or IL-2 (20 IU/
ml) from days 1–8 of culture, followed by T cell expansion using
OKT3 starting on day 14 and IL-2 (1000 U/ml) when T cells rep-
resented. 99% of all cells present, for up to 42 d. CTL activity was
assessed by lysis of 51-Cr labeled autologous AML-blasts and by
overnight generation of IFN-g. Results:Using this system we pre-
viously showed (n5 18) that CD331AMLblasts decreased from 80
6 28% preculture to\1% on d 35 while CD31 T cells increased
from 3% to . 99%. CTL produced 42 6 23% lysis of autologous
AML blasts at an Effector:Target (E:T) ratio 5 20:1 and was
blocked by anti-MHC class-I, but not MHC class II. CTL caused
\ 5% lysis of autologous PHA blasts and non-hematopoietic cells.
Incubation of CTL with autologous AML blasts decreased colony
growth .95% at E:T 5 2:1 (n 5 3). We now show, in cultures
from 7 different AML patients that the mean IFN-g generation us-
ing IL-2 during days 1–8 of culture was similar to that using anti-
CTLA-4 (2436 244 pg/ml vs 2546 335; p5 0.9) and in 2 studies
(12–24 replicates) that AML cell lysis using CTL generated with
IL-2 was similar to that with anti-CTLA-4 (30 6 13% vs 26 6
12; p5 0.2).Conclusion: A novel AML culture method employing
DC differentiation of AML cells followed by T cell expansion gen-
erated CTL that were highly reactive to autologous AML blasts. In-
clusion of low dose IL-2 early during culture was equally as effective
as anti-CTLA-4 in activating the CTL. This finding will facilitate
the design and conduct of immunotherapy trials of autologous ex-
panded CTL in patients with AML.151
MECHANISM OF BUSULFAN RESISTANCE OF MYELOID LEUKEMIA CELLS
Valdez, B.C.1, Murray, D.3, Ramdas, L.2, de Lima, M.1, Jones, R.1,
Kornblau, S.1, Betancourt, D.1, Li, Y.1, Champlin, R.E.1,Andersson, B.S.1 1UT MD Anderson Cancer Center, Houston, TX;
2UT MD Anderson Cancer Center, Houston, TX; 3Cross Cancer Insti-
tute, Edmonton, AB, Canada.
Busulfan (Bu) resistance is amajor obstacle to hematopoietic stem
cell transplantation (HSCT) of patients withmyelogenous leukemia
(CML and AML/MDS). To study cellular resistance phenomena
we established two Bu-resistant leukemia cell lines that were pheno-
typically characterized. The CML B5/Bu2506 cells are 4.5-fold
more resistant to Bu than their parental B5 cells. The AML
KBM3/Bu2506 cells are 4.0-fold more Bu-resistant than KBM3 pa-
rental cells.We then used gene expression analysis to identify differ-
entially expressed genes associated with Bu resistance. The results
suggest that Bu resistance is multifactorial and includes constitu-
tively up-regulated expression of genes involved in anti-apoptotis
(BCL-XL, BCL2, BCL2L10, BAG3 and IAP2/BIRC3), stress re-
sponse (HSP90 and STAT3), busulfan metabolism (GSTM), and
DNA repair (PARP1, ATM and Ku70/80). Furthermore, the Bu-re-
sistant sublines evade Bu-mediated G2-arrest and caspase-depen-
dent apoptosis. GSTM3 is up-regulated in KBM3/Bu2506 cells;
its ectopic expression in the KBM3 parental cell line imparts partial
resistance to Bu. Inhibitors of HSP90 activity, STAT3 phosphory-
lation and PARP1 functions were found to sensitize busulfan-resis-
tant cells. The role of DNA break repair on Bu resistance is
currently being investigated. Analysis of cells derived from patients
classified as either clinically resistant or sensitive to high-dose Bu-
based chemotherapy indicated alterations in gene expression that
were analogous to those observed in the in-vitro model cell lines,
confirming the clinical relevance of this model formechanistic stud-
ies of cellular Bu resistance.152
LONG TERM REMISSION IN PHILADELPHIA-POSITIVE ACUTE LYMPHO-
BLASTIC LEUKEMIA (Ph1 ALL) PATIENTS AFTER ALLOGENEIC MYE-
LOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (HCT) USING
MATCHED RELATED DONORS: THE 20 YEAR EXPERIENCE AT STANFORD
UNIVERSITY AND CITY OF HOPE NATIONAL MEDICAL CENTER
Laport, G.G.1, Alvarnas, J.C.2, Palmer, J.M.2, Snyder, D.S.2,
Slovak, M.L.2, Cherry, A.M.1, Negrin, R.S.1, Blume, K.G.1,
Forman, S.J.2 1Stanford University Medical Center, Stanford, CA;
2City of Hope National Medical Center, Duarte, CA.
Due to the inherently poor prognoses of patients with Philadel-
phia-positive ALL, allogeneic HCT is offered early in their treat-
ment course if a suitable donor is available. We report the 20 year
experience from 1985 to 2005 at Stanford University and City of
Hope National Medical Center in which 79 patients with matched
related donors received a myeloablative conditioning regimen. The
median age of all patients (pts) was 36 years (range 2–57 years). At
the time of HCT, forty-nine pts (62%) were in first complete remis-
sion (CR1) and 30 pts (38%) were beyond CR1 (.CR1). The ma-
jority of pts (85%) received the conditioning regimen of
fractionated total body irradiation (FTBI, dose 5 1320 cGy) and
high dose VP16 (60 mg/kg), 11 (14%) patients received FTBI/
VP16/cyclophosphamide and one patient received the FTBI/V16/
busulfan regimen (1%). The most commonly used graft vs host dis-
ease (GVHD) prophylaxis regimens were cyclosporine (CSA) and
methotrexate (47%) and CSA/methotrexate/methylprednisolone
(29%). The 10-year outcomes are listed in the table below. At diag-
nosis, forty percent of pts had chromosomal abnormalities in addi-
tion to t(9;22) but this was not found to affect survival outcomes.
Pre-HCT factors that significantly affected event free survival
(EFS) and overall survival (OS) were WBC at diagnosis (\30,000
vs $30,000) and disease status (CR1 vs .CR1). The development
of grade 2–4 acute GVHD was an adverse factor for DFS and OS
by both univariate and multivariate analysis. Factors significantly
associated with increased nonrelapse mortality (NRM) were a his-
tory of radiation therapy prior to HCT for extramedullary disease
and disease status with the .CR1 pts experiencing a significantly
higher NRM. The inferior EFS and OS for the .CR1 pts was at-
tributed to the higher NRM. The median time to relapse for the
CR1 patients was 12 months (range, 1–27 months) and for the
.1CR patients was 9 months (range, 3–19 months) indicating
